GLP-1 incretin analogues are on the market as treatments for diabetes.
•
First clinical trials show good effects in patients with Parkinson′s.
•
Novel dual-agonists have been developed that are superior.
•
We show that a novel GLP-1/GIP analogue shows good effects in a mouse model of PD.
•
Motor activity is protected, BDNF levels and Akt activity is increased by the drug.
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.